Atopic Dermatitis Market
To improve the website's functionality, we use cookies, including third-party cookies. Read our Privacy Policy for more information
I Agree
Atopic Dermatitis Market
Analysis of Atopic Dermatitis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary : Global Market 4. Market Overview 4.1. Introduction 4.1.1. Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Market Analysis and Forecasts, 2022–2032 5. Market Outlook 5.1. Disease Epidemiology 5.2. Pipeline Analysis 5.3. Recent Development 6. Global Market Analysis and Forecasts, by Drug Class 6.1. Introduction & Definition 6.2. Market Value Forecast by Drug Class, 2022–2032 6.2.1. Corticosteroids 6.2.2. PDE4 Inhibitors 6.2.3. Biologics 6.2.4. Skin Barrier Emollients 6.2.5. CNI Immunosuppressants 6.2.6. Others 6.3. Market Attractiveness by Drug Class 7. Global Market Analysis and Forecasts, by Distribution Channel 7.1. Introduction & Definition 7.2. Market Value Forecast by Distribution Channel, 2022–2032 7.2.1. Hospital Pharmacies 7.2.2. Retail Pharmacies 7.2.3. Online Pharmacies 7.3. Market Attractiveness by Distribution Channel 8. Global Market Analysis and Forecasts, by Region 8.1. Key Findings 8.2. Market Value Forecast by Region 8.2.1. North America 8.2.2. Europe 8.2.3. Asia Pacific 8.2.4. Latin America 8.2.5. Middle East & Africa 8.3. Market Attractiveness by Country/Region 9. North America Market Analysis and Forecast 9.1. Introduction 9.2. Market Value Forecast by Drug Class, 2022–2032 9.2.1. Corticosteroids 9.2.2. PDE4 Inhibitors 9.2.3. Biologics 9.2.4. Skin Barrier Emollients 9.2.5. CNI Immunosuppressants 9.2.6. Others 9.3. Market Value Forecast by Distribution Channel, 2022–2032 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.4. Market Value Forecast by Country, 2022–2032 9.4.1. U.S. 9.4.2. Canada 9.5. Market Attractiveness Analysis 9.5.1. By Drug Class 9.5.2. By Distribution Channel 9.5.3. By Country 10. Europe Market Analysis and Forecast 10.1. Introduction 10.2. Market Value Forecast by Drug Class, 2022–2032 10.2.1. Corticosteroids 10.2.2. PDE4 Inhibitors 10.2.3. Biologics 10.2.4. Skin Barrier Emollients 10.2.5. CNI Immunosuppressants 10.2.6. Others 10.3. Market Value Forecast by Distribution Channel, 2022–2032 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Online Pharmacies 10.4. Market Value Forecast by Country/Sub-region, 2022–2032 10.4.1. Germany 10.4.2. U.K. 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Rest of Europe 10.5. Market Attractiveness Analysis 10.5.1. By Drug Class 10.5.2. By Distribution Channel 10.5.3. By Country/Sub-region 11. Asia Pacific Market Analysis and Forecast 11.1. Introduction 11.2. Market Value Forecast by Drug Class, 2022–2032 11.2.1. Corticosteroids 11.2.2. PDE4 Inhibitors 11.2.3. Biologics 11.2.4. Skin Barrier Emollients 11.2.5. CNI Immunosuppressants 11.2.6. Others 11.3. Market Value Forecast by Distribution Channel, 2022–2032 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies 11.3.3. Online Pharmacies 11.4. Market Value Forecast by Country/Sub-region, 2022–2032 11.4.1. China 11.4.2. Japan 11.4.3. India 11.4.4. Australia & New Zealand 11.4.5. Rest of Asia Pacific 11.5. Market Attractiveness Analysis 11.5.1. By Drug Class 11.5.2. By Distribution Channel 11.5.3. By Country/Sub-region 12. Latin America Market Analysis and Forecast 12.1. Introduction 12.2. Market Value Forecast by Drug Class, 2022–2032 12.2.1. Corticosteroids 12.2.2. PDE4 Inhibitors 12.2.3. Biologics 12.2.4. Skin Barrier Emollients 12.2.5. CNI Immunosuppressants 12.2.6. Others 12.3. Market Value Forecast by Distribution Channel, 2022–2032 12.3.1. Hospital Pharmacies 12.3.2. Retail Pharmacies 12.3.3. Online Pharmacies 12.4. Market Value Forecast by Country/Sub-region, 2022–2032 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Rest of Latin America 12.5. Market Attractiveness Analysis 12.5.1. By Drug Class 12.5.2. By Distribution Channel 12.5.3. By Country/Sub-region 13. Middle East & Africa Market Analysis and Forecast 13.1. Introduction 13.2. Market Value Forecast by Drug Class, 2022–2032 13.2.1. Corticosteroids 13.2.2. PDE4 Inhibitors 13.2.3. Biologics 13.2.4. Skin Barrier Emollients 13.2.5. CNI Immunosuppressants 13.2.6. Others 13.3. Market Value Forecast by Distribution Channel, 2022–2032 13.3.1. Hospital Pharmacies 13.3.2. Retail Pharmacies 13.3.3. Online Pharmacies 13.4. Market Value Forecast by Country/Sub-region, 2022–2032 13.4.1. GCC Countries 13.4.2. South Africa 13.4.3. Rest of Middle East & Africa 13.5. Market Attractiveness Analysis 13.5.1. By Drug Class 13.5.2. By Distribution Channel 13.5.3. By Country/Sub-region 14. Competitive Landscape 14.1. Company Profiles 14.1.1. Mylan N.V. 14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.1.2. Product Portfolio 14.1.1.3. SWOT Analysis 14.1.1.4. Strategic Overview 14.1.1.5. Financial Overview 14.1.2. Pfizer, Inc. 14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.2.2. Product Portfolio 14.1.2.3. SWOT Analysis 14.1.2.4. Strategic Overview 14.1.2.5. Financial Overview 14.1.3. LEO Pharma A/S 14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.3.2. Product Portfolio 14.1.3.3. SWOT Analysis 14.1.3.4. Strategic Overview 14.1.3.5. Financial Overview 14.1.4. Teva Pharmaceutical Industries Ltd 14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.4.2. Product Portfolio 14.1.4.3. SWOT Analysis 14.1.4.4. Strategic Overview 14.1.4.5. Financial Overview 14.1.5. Sanofi 14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.5.2. Product Portfolio 14.1.5.3. SWOT Analysis 14.1.5.4. Strategic Overview 14.1.5.5. Financial Overview 14.1.6. Novartis AG 14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.6.2. Product Portfolio 14.1.6.3. SWOT Analysis 14.1.6.4. Strategic Overview 14.1.6.5. Financial Overview
Don't Need a Global Report?
Save 40% on Country & Region specific reports
Table 01: Global Market Value (US$ Mn) Forecast, by Drug Class, 2022–2032
Table 02: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032
Table 03: Global Market Value (US$ Mn) Forecast, by Region, 2022–2032
Table 04: North America Market Value (US$ Mn) Forecast, by Country, 2022–2032
Table 05: North America Value (US$ Mn) Forecast, by Drug Class, 2022–2032
Table 06: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032
Table 07: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032
Table 08: Europe Value (US$ Mn) Forecast, by Drug Class, 2022–2032
Table 09: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032
Table 10: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032
Table 11: Asia Pacific Value (US$ Mn) Forecast, by Drug Class, 2022–2032
Table 12: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032
Table 13: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032
Table 14: Latin America Value (US$ Mn) Forecast, by Drug Class, 2022–2032
Table 15: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032
Table 16: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032
Table 17: Middle East & Africa Value (US$ Mn) Forecast, by Drug Class, 2022–2032
Table 18: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Figure 01: Global Market Snapshot
Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2022 and 2027
Figure 03: Global Market Value (US$ Mn) Forecast, 2022–2032
Figure 04: Global Market Value Share (%), by Drug Class (2022)
Figure 05: Global Market Value Share (%), by Distribution Channel (2022)
Figure 06: Global Market Value Share (%), by Region (2022)
Figure 07: Global Market Value Share Analysis, by Drug Class, 2022 and 2027
Figure 08: Global Market Attractiveness, by Drug Class, 2022–2027
Figure 09: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2022–2032
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2022–2032
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biologics, 2022–2032
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Barrier Emollients, 2022–2032
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNI Immunosuppressants, 2022–2032
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022–2032
Figure 15: Global Market Value Share (%), by Distribution Channel, 2022 and 2027
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2022–2032
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2022–2032
Figure 18: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2022–2032
Figure 19: Global Market Attractiveness, by Distribution Channel, 2022–2027
Figure 20: Global Market Value Share Analysis, by Region, 2022 and 2027
Figure 21: Global Market Attractiveness, by Region, 2022–2027
Figure 22: North America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032
Figure 23: North America Market Value Share (%), by Country, 2022 and 2027
Figure 24: North America Market Attractiveness, by Country, 2022–2027
Figure 25: North America Market Value Share (%), by Drug Class, 2022 and 2027
Figure 26: North America Market Attractiveness, by Drug Class, 2022–2027
Figure 27: North America Market Value Share (%), by Distribution Channel, 2022 and 2027
Figure 28: North America Market Attractiveness, by Distribution Channel, 2022–2027
Figure 29: Europe Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032
Figure 30: Europe Market Value Share (%), by Country/Sub-region, 2022 and 2027
Figure 31: Europe Market Attractiveness, by Country/Sub-region, 2022–2027
Figure 32: Europe Market Value Share (%), by Drug Class, 2022 and 2027
Figure 33: Europe Market Attractiveness, by Drug Class, 2022–2027
Figure 34: Europe Market Value Share (%), by Distribution Channel, 2022 and 2027
Figure 35: Europe Market Attractiveness, by Distribution Channel, 2022–2027
Figure 36: Asia Pacific Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032
Figure 37: Asia Pacific Market Value Share (%), by Country/Sub-region, 2022 and 2027
Figure 38: Asia Pacific Market Attractiveness, by Country/Sub-region, 2022–2027
Figure 39: Asia Pacific Market Value Share (%), by Drug Class, 2022 and 2027
Figure 40: Asia Pacific Market Attractiveness, by Drug Class, 2022–2027
Figure 41: Asia Pacific Market Value Share (%), by Distribution Channel, 2022 and 2027
Figure 42: Asia Pacific Market Attractiveness, by Distribution Channel, 2022–2027
Figure 43: Latin America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020-2027
Figure 44: Latin America Market Value Share (%), by Country/Sub-region 2022 and 2027
Figure 45: Latin America Market Attractiveness, by Country/Sub-region, 2022–2027
Figure 46: Latin America Market Value Share (%), by Drug Class, 2022 and 2027
Figure 47: Latin America Market Attractiveness, by Drug Class, 2022–2027
Figure 48: Latin America Market Value Share (%), by Distribution Channel, 2022 and 2027
Figure 49: Latin America Market Attractiveness, by Distribution Channel, 2022–2027
Figure 50: Middle East & Africa Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032
Figure 51: Middle East & Africa Market Value Share (%), by Country/Sub-region 2022 and 2032
Figure 52: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2022–2032
Figure 53: Middle East & Africa Market Value Share (%), by Drug Class, 2022 and 2032
Figure 54: Middle East & Africa Market Attractiveness, by Drug Class, 2022–2032
Figure 55: Middle East & Africa Market Value Share (%), by Distribution Channel, 2022 and 2032
Figure 56: Middle East & Africa Market Attractiveness, by Distribution Channel, 2022–2032
Figure 57: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021
Figure 58: Mylan N.V. R&D Expenses (US$ Mn), 2016–2018
Figure 59: Mylan N.V. Breakdown of Net Sales (%), by Region, 2018
Figure 60: Mylan N.V. Breakdown of Net Sales (%), by Business Segment, 2018
Figure 61: Pfizer, Inc. Breakdown of Net Sales, by Region, 2018
Figure 62: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2018
Figure 63: Pfizer, Inc. R&D Expenses (US$ Mn), 2016–2018
Figure 64: LEO Pharma A/S Breakdown of Net Sales, by Region (2018)
Figure 65: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2018)
Figure 66: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2018
Figure 67: LEO Pharma A/S R&D Expenses (US$ Mn), 2016–2018
Figure 68: Sanofi Revenue (US$ Bn), 2015–2018
Figure 69: Sanofi Regional Sales Breakdown (%), 2018
Figure 70: Novartis AG Breakdown of Net Sales, by Region, 2018
Figure 71: Novartis AG Breakdown of Net Sales, by Business Segment, 2018
Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018
Figure 73: Novartis AG R&D Expenses (US$ Mn), 2016–2018
Figure 74: Teva Pharmaceutical Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2018
Figure 75: Teva Pharmaceutical R&D Expenses (US$ Mn), 2016–2018
Figure 76: Teva Pharmaceutical Breakdown of Net Sales, by Region, 2018
Figure 77: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2018
Know thy Competitors
Competitive landscape highlights only certain players.
Complete list available upon request
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunities
Buy NowGet A Special pricing for start-ups and universities
Enquiry Before Buying- Humble, Yet Honored -
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
